Mangoceuticals, Inc. Form 8-K Summary
Business context and reporting period
Mangoceuticals, Inc. filed a Form 8-K reporting a Nasdaq continued-listing deficiency. The earliest reported event occurred on October 30, 2023. The company’s common stock trades on the Nasdaq Capital Market under the symbol MGRX.
Financial metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial statement metrics.
Material changes versus the prior comparable period
On October 30, 2023, Nasdaq notified the company that its common stock no longer satisfied the minimum bid-price requirement under Nasdaq Listing Rule 5550(a)(2). The deficiency was based on closing bid prices below $1.00 for 30 consecutive business days from September 15 through October 27, 2023.
Guidance, outlook, risks, contingencies, and unusual items
- The notice does not immediately affect the company’s Nasdaq listing.
- The company has until April 29, 2024, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
- Nasdaq may grant an additional 180-day compliance period if the company meets applicable initial-listing criteria, excluding the bid-price requirement, and notifies Nasdaq of its intention to cure the deficiency, potentially through a reverse stock split.
- If the company does not qualify for or complete the additional compliance period, its common stock could be subject to delisting, with an opportunity to appeal to a Nasdaq Hearings Panel.
- The company stated that it intends to monitor its closing bid price and may consider available actions to regain compliance.
Key facts for investors to verify
- Whether MGRX’s closing bid price reaches at least $1.00 for the required 10 consecutive business days.
- Whether Nasdaq grants an additional compliance period after April 29, 2024.
- Whether the company implements a reverse stock split or another corporate action to address the deficiency.
- Any subsequent Nasdaq delisting notice, hearing request, or compliance determination.